A month after exiting from the microarray manufacturing sector, Incyte has signaled its intention to move further into the pharmaceutical arena by appointing a pair of big pharma executives to top positions. Paul Friedman, the former president of DuPont Pharmaceuticals Research Laboratories, is the new chief executive officer, replacing Roy Whitfield. Robert Stein, DuPont Pharmaceuticals’ former executive vice president of research and preclinical development, will serve as president and chief scientific officer.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.